GSK vs SPRY · P/E 13, $103.31B cap vs rev $56.3M
GlaxoSmithKline PLC ADR (GSK) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
GSK does not have a complete income-statement cache yet.
Latest reported SPRY revenue for 2026-06-30 was $56.3M. Net income was -$123.0M. SPRY currently screens at market cap $983.1M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the GSK and SPRY stock pages for the full models.
Not investment advice.